Aviva Systems Biology’s Post

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry–based de novo sequencing. Monoclonal antibodies against the MUC1 VNTR are powerful research tools with applications in the diagnosis and treatment of MUC1-expressing cancers. In this research, scientist report direct mass spectrometry–based sequencing of anti-MUC1 hybridoma-derived 139H2 IgG, enabling reverse-engineering of the functional recombinant monoclonal antibody. https://hubs.ly/Q02qBxk50

Nature Reviews Drug Discovery at Springer Nature Group and Nature Portfolio highlights the latest publication of our co-founders Luis Alvarez-Vallina and Belén Blanco Durango on STAb Technology for the treatment of #multiplemyeloma. This research highlight recaps the most relevant results obtained in the preclinical study showing the superiority of STAb-TBCMA compared to CAR T cells against the same target. As our co-founder underscores in the research highlight: “In this strategy, T cell recruitment is not restricted to engineered T cells (…). The polyclonal recruitment by TCEs of both engineered and unmodified bystander T cells, present at the tumour site, lead to a significant boost in antitumour T cell responses”. We are eager to continue the development of our product STAb-TBCMA and the development of our #STAbTechnology for other cancer types. You can access the Research Highlight here: https://lnkd.in/duXK4BJE For the original paper on STAb-TBCMA: https://lnkd.in/e38ugSjW   #immunotherapy #cancertherapeutics #multiplemyeloma #immunooncology #celltherapy

Let's talk about ERBB2/HER2, the pan-cancer gene popping up in a whopping 21 types of human cancer! 🔬 Atlas Antibodies has the ultimate arsenal of primary antibodies ready to tag it: 👉 PrecisA Monoclonal antibody AMAb90627 (https://ow.ly/SM8q50RqFOS) Triple A Polyclonal antibodies 👉 HPA001338 (https://ow.ly/B47L50RqFOT) 👉 HPA001383 (https://ow.ly/PyqE50RqFOU) Find out more about Pan-Cancer Markers and choose the best for your research. https://ow.ly/vkK250RqFOV Download the eBook "Pan-Cancer Markers for Proteomic Phenotyping” 📖 : https://ow.ly/vkK250RqFOV 💻 Unlock a stellar 15% discount when you shop in our web store: https://ow.ly/a1hF50RqFOW #cancer #carcinoma #Research #Antibodies #Science #BulkOrder #DiscountOffer #CancerResearch #Proteomicphenotyping #PanCancerMarkers #atlasantibodies #PrecisAMonoclonals #TripleAPolyclonals #immunohistochemistry #westernblot #immunocytochemistry

🌟 Exciting News for Peptide Enthusiasts! 🌟 Begin your year with a burst of knowledge! Our January 2024 roundup offers a concise 10-minute summary of the top 10 breakthroughs in peptide research. From revolutionary cancer treatments to breakthroughs in peptide drug synthesis, our latest update covers it all. 🔍 Discover insights on: Bicyclic peptides inhibiting the MYC protein, a key player in human cancers. Innovative approaches in cyclic peptide drug synthesis targeting challenging proteins. The latest developments in cancer vaccine research utilizing circular RNA. And more! Stay ahead in the fast-evolving field of peptide research and join us in exploring these groundbreaking developments. 👉 Read the full articles and dive into the fascinating world of peptides here: [https://lnkd.in/dBXENcsF] #Peptides #CancerResearch #DrugSynthesis #VaccineDevelopment #PeptideScience #HealthcareInnovation #Biotechnology #January2024Update

🥁 POSTER | An automated standardized screening workflow for assessing combination therapies in human pancreatic cancer #organoids A vast majority of cancer patients still lack efficient therapy options with lasting benefit. With the rise of #personalizedmedicine, there is still an unmet need to develop efficient assays for testing tumor response to different treatments within clinically actionable timeframe, and in the available tumor volume. 👩🔬 Using SUN bioscience's #Gri3D microwell plates, a #standardized and #automated screening workflow was implemented to assess single and combination therapies in pancreatic cancer organoids. With this #highthroughput drug screening system, it was shown that combination therapies allow a reduction of secondary effects by lowering the doses of the single agents, while avoiding resistance. 📚 Learn more by reading the poster here: https://lnkd.in/eFvFPdbf - or drop us a message and we will be glad to discuss some science with you! #3Dcellculture #organoids #biotechnology #research #clinicalresearch #drugscreening #patientderivedorganoids 

Our 2024 paper is out now! https://lnkd.in/gQr_UzT5 We integrated molecular dynamics simulation with coarse-grained and temperature control to explore the conformational landscape of these complex interactions. The per-residue-energy-binding emphasised the crucial amino acids involved in binding within the complex especially between the complementarity-determining regions (CDR) of BiTEs and residues located at the N-terminal of CD117/c-kit and the C-terminal of CD3. This method is a valuable tool for rational drug design especially in the field of cancer immunotherapy. Special thanks to ColabFold v1.5.5: AlphaFold2 using MMseqs2 https://lnkd.in/gVfwbCbp ClusPro 2.0: Protein-Protein Docking https://lnkd.in/gUVBGptS Heated Dynamics https://lnkd.in/gGBqwyk3 gmx_MMPBSA https://lnkd.in/g2NnMaq5

Our VP Preclinical Development & Translation Strategy, Thorsten Ross, is looking forward to his presentation next week at the Federation of American Societies for Experimental Biology (FASEB)’s Scientific Research Conference focusing on the TGF-β Superfamily. In his talk on July 22, he will outline our latest findings demonstrating that GDF-15, a member of this cytokine family, is a central mediator of #cancer treatment resistance and toxicity in platinum-based #chemotherapy, which is commonly used alongside PD-1 checkpoint inhibitors in the first-line treatment of advanced #NSCLC. Our preclinical findings showcase the potential of our lead antibody candidate visugromab, a first-in-class GDF-15-blocking antibody, to enhance responses and tolerability of standard-of-care chemoimmunotherapy. Find the full agenda details here https://bit.ly/45Z5aD1 and learn more about our novel strategy to counteract resistance and improve #SolidTumor #patient outcomes at www.catalym.com #TGFSRC

Congratulations to Curve Therapeutics CSO Ali Tavassoli, who recently co-authored an academic paper that has been published in the Journal of the American Chemical Society! Titled 'Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and 2 That Disrupt Hypoxia-Related Signalling in Cancer Cells', the paper underlines the promising therapeutic potential of dual HIF inhibition as an approach for the treatment of a variety of cancers. This is the first report of a dual HIF-1 and HIF-2 inhibitor which functions by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β. The research stems from the stellar work undertaken by Professor Tavassoli's laboratory at the University of Southampton. The Microcycles discovered by Prof. Tavassoli were identified using his SICLOPPS screening platform and you can read the full report via the link in the comments. #research #cancer 

Thrilled to announce that we were selected to present a poster higlighting preliminary results from our Phase 1 study of Decoy20 at the 2024 ASCO Annual Meeting in Chicago from May 31 – June 4. Decoy20 employs a novel approach by using killed, non-pathogenic bacteria to activate the immune system against tumors, and could offer a significant advancement in immuno-oncology. Please stop by to see us at the conference, and stay tuned for more updates! Presentation Details: Title: Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors. Session: Poster Session in the Developmental Therapeutics—Immunotherapy track. Abstract Number: 2583 Poster Board Number: 62 Clinical Trial Registration: NCT05651022 #IndaptusTherapeutics #ASCO2024 #CancerResearch #Immunotherapy #Decoy20